drugset / Trial / NCT01424397

Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

NCT01424397

Phase 2 Completed 70 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.

Timeline

Start
2011-04-14
Primary completion
2011-07-07
Completion
2011-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 200 ug Intranasal
Subject SB-705498 Small molecule 12 mg Intranasal

Indications